Cargando…

Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential

Multiple myeloma is the second most frequent hematological malignancy in the western world and remains incurable, predominantly due to acquired drug resistance and disease relapse. The highly conserved Wnt signal transduction pathway, which plays a key role in regulating cellular processes of prolif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spaan, Ingrid, Raymakers, Reinier A., van de Stolpe, Anja, Peperzak, Victor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960217/ https://www.ncbi.nlm.nih.gov/pubmed/29776381 http://dx.doi.org/10.1186/s13045-018-0615-3

Ejemplares similares

Multiple Myeloma Relapse Is Associated with Increased NFκB Pathway Activity and Upregulation of the Pro-Survival BCL-2 Protein BFL-1
por: Spaan, Ingrid, et al.
Publicado: (2021)

Wnt inhibitors reduce the unfolded protein response and enhance bortezomib-induced cell death in multiple myeloma
por: Spaan, Ingrid, et al.
Publicado: (2022)

Role and Regulation of Pro-survival BCL-2 Proteins in Multiple Myeloma
por: Slomp, Anne, et al.
Publicado: (2018)

Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma
por: Lütje, Susanne, et al.
Publicado: (2009)

Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients
por: Oostvogels, Rimke, et al.
Publicado: (2018)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options
por: van Andel, Harmen, et al.
Publicado: (2019)

Targeting B-cell maturation antigen increases sensitivity of multiple myeloma cells to MCL-1 inhibition
por: Cuenca, Marta, et al.
Publicado: (2021)

Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells
por: Slomp, Anne, et al.
Publicado: (2021)

MicroRNAs: New Players in Multiple Myeloma
por: Pichiorri, Flavia, et al.
Publicado: (2011)

Transcriptional Silencing of the Wnt-Antagonist DKK1 by Promoter Methylation Is Associated with Enhanced Wnt Signaling in Advanced Multiple Myeloma
por: Kocemba, Kinga A., et al.
Publicado: (2012)

Falsely decreased ferritin concentrations in two patients with haemophagocytic lymphohistiocytosis: A case report
por: Roozen, Geert, et al.
Publicado: (2018)

Possible Therapeutic Potential of Disulfiram for Multiple Myeloma
por: Weiser Drozdkova, Denisa, et al.
Publicado: (2021)

Multiple Myeloma Macrophages: Pivotal Players in the Tumor Microenvironment
por: Berardi, Simona, et al.
Publicado: (2013)

MicroRNA: Important Player in the Pathobiology of Multiple Myeloma
por: Bi, Chonglei, et al.
Publicado: (2014)

Proteasome inhibition and its therapeutic potential in multiple myeloma
por: Chari, Ajai, et al.
Publicado: (2010)

The therapeutic potential of cell cycle targeting in multiple myeloma
por: Maes, Anke, et al.
Publicado: (2017)

Quantitative Measurement of Functional Activity of the PI3K Signaling Pathway in Cancer
por: van de Stolpe, Anja
Publicado: (2019)

Silencing RRM2 inhibits multiple myeloma by targeting the Wnt/β-catenin signaling pathway
por: Liu, Xia, et al.
Publicado: (2019)

Microenvironment drug resistance in multiple myeloma: emerging new players
por: Di Marzo, Lucia, et al.
Publicado: (2016)

p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
por: Teoh, P. J., et al.
Publicado: (2014)

Identification of potential glucocorticoid receptor therapeutic targets in multiple myeloma
por: Thomas, Alexandra L., et al.
Publicado: (2015)

Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2021)

Therapeutic Advancements in Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2014)

Targeting IL-17A in Multiple Myeloma: A Potential Novel Therapeutic Approach in Myeloma
por: Prabhala, Rao H., et al.
Publicado: (2015)

RNA processing: a new player of genomic instability in multiple myeloma
por: Marchesini, Matteo, et al.
Publicado: (2017)

The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential
por: Bieghs, Liesbeth, et al.
Publicado: (2016)

Nucleotide excision repair is a potential therapeutic target in multiple myeloma
por: Szalat, R, et al.
Publicado: (2018)

The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma
por: Zhu, Bingying, et al.
Publicado: (2018)

Potential Therapeutic Roles of Exosomes in Multiple Myeloma: A Systematic Review
por: Li, Mengzhen, et al.
Publicado: (2019)

The Potential of JAG Ligands as Therapeutic Targets and Predictive Biomarkers in Multiple Myeloma
por: Platonova, Natalia, et al.
Publicado: (2023)

Vitamin D as a Potential Player in Immunologic Control over Multiple Myeloma Cells: Implications for Adjuvant Therapies
por: Kulig, Piotr, et al.
Publicado: (2022)

Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma
por: Patel, Urmeel H., et al.
Publicado: (2015)

Multiple myeloma with central nervous system relapse
por: Egan, Philip A., et al.
Publicado: (2020)

Canonical Wnt Pathway Inhibitor ICG-001 Induces Cytotoxicity of Multiple Myeloma Cells in Wnt-Independent Manner
por: Grigson, Eileen R., et al.
Publicado: (2015)

Notch and Wnt Signaling Modulation to Enhance DPSC Stemness and Therapeutic Potential
por: Uribe-Etxebarria, Verónica, et al.
Publicado: (2023)

Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma
por: Zeissig, Mara N., et al.
Publicado: (2020)

Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma
por: Ma, Jian, et al.
Publicado: (2011)

Role of Sphingolipids in Multiple Myeloma Progression, Drug Resistance, and Their Potential as Therapeutic Targets
por: Petrusca, Daniela N., et al.
Publicado: (2022)

Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date
por: Mann, Hashim, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9dl2ng8o0e5m11abbrvt1f86gh